Welcome to our dedicated page for Alto Neuroscienc news (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on Alto Neuroscienc stock.
Alto Neuroscience Inc. (NYSE: ANRO) is a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, and the ANRO news page on Stock Titan aggregates company-specific updates and disclosures. Alto regularly issues press releases on its clinical programs, biomarker research, regulatory designations, and financing activities, providing investors and observers with insight into its progress in precision psychiatry.
News coverage for Alto commonly includes clinical trial milestones for product candidates such as ALTO-207, ALTO-101, ALTO-100, ALTO-300, and ALTO-203. These updates may describe outcomes of FDA meetings, initiation or advancement of Phase 2 and Phase 3 studies, pharmacokinetic analyses, and proof-of-concept data in areas like treatment-resistant depression, bipolar depression, major depressive disorder, and cognitive impairment associated with schizophrenia. Alto also reports on validation of EEG biomarkers, including theta-band inter-trial coherence, and their use as primary outcomes in ongoing studies.
In addition to clinical data, Alto’s news releases cover regulatory and intellectual property developments, such as Fast Track designation for ALTO-101 in CIAS and the issuance of U.S. patents related to ALTO-207. Corporate and capital markets updates, including private placement financings, option repricings, board appointments, and inducement equity grants under NYSE rules, are also disclosed through company news.
This ANRO news feed allows readers to follow Alto Neuroscience’s reported developments in real time, from scientific presentations at conferences to investor events and SEC-related announcements. Users interested in biotechnology, neuropsychiatric drug development, and biomarker-driven clinical research can review these items to understand how Alto communicates its pipeline evolution and corporate actions.
Alto Neuroscience announced the initiation of a Phase 2 trial for ALTO-101, a PDE4 inhibitor aimed at treating cognitive impairment in schizophrenia. The study, expected to conclude by the second half of 2025, will involve 70 adults and compare a transdermal formulation of ALTO-101 against a placebo. Previous Phase 1 trials showed positive cognitive effects and fewer adverse events compared to oral administration. CEO Amit Etkin highlighted the potential of ALTO-101 to improve cognitive function across various psychiatric disorders.
The primary outcome will measure the effect on theta band activity using EEG. This follows promising data presented at the SOBP Annual Meeting, affirming the relevance of EEG measures in assessing cognitive function in schizophrenia.
Amit Etkin, M.D., Ph.D., founder and CEO of Alto Neuroscience, was named an EY Entrepreneur Of The Year 2024 Bay Area Award winner. Dr. Etkin was selected from a pool of 26 finalists by an independent panel of judges. The award celebrates innovative leaders across various industries. Alto Neuroscience, under Dr. Etkin's leadership, has been recognized for its mission to advance precision psychiatry. The winners were evaluated based on entrepreneurial spirit, purpose, growth, and impact. Regional winners, announced on June 14, 2024, will now compete for the National Awards in November.
Alto Neuroscience (NYSE: ANRO) announced its participation in the Jefferies Global Healthcare Conference in New York from June 5-6, 2024. Founder and CEO Amit Etkin, M.D., Ph.D., will engage in a fireside chat on June 6, 2024, at 2:30 p.m. ET. Additionally, the company's management will hold one-on-one meetings with investors. A live webcast of the discussion will be available on Alto's investor relations webpage, with a replay accessible afterward.
Alto Neuroscience (NYSE: ANRO) has appointed Michael Hanley as its new Chief Operating Officer (COO). Hanley brings over 25 years of expertise in the life sciences industry, particularly in neuropsychiatric conditions like major depressive disorder and schizophrenia. His role will involve new product planning, portfolio strategy, and cross-functional leadership to enhance Alto's clinical-stage programs and biomarker platform. Hanley's extensive background includes leadership positions at Aeglea BioTherapeutics and Horizon Therapeutics. He holds a Bachelor of Business Administration from the University of Notre Dame and an MBA from Kellogg School of Management.
Alto Neuroscience (NYSE: ANRO) announced its Q1 2024 financial results and recent business updates. The company initiated a Phase 2 study of ALTO-203 for MDD and anhedonia, and reported positive Phase 1 data for the transdermal formulation of ALTO-101, showing improved drug exposure and tolerability. Patient enrollment for ALTO-100 and ALTO-300 Phase 2b MDD studies is progressing well. The company has a strong cash position of approximately $206 million, expected to support operations into 2027.
Alto's ongoing studies include ALTO-100 and ALTO-300, both targeting MDD, and ALTO-101 for CIAS. The company also announced the initiation of a Phase 2 proof-of-concept study for ALTO-203 in patients with MDD and high levels of anhedonia. Financial highlights include a net loss of $13.4 million, an increase in R&D expenses to $10 million, and higher G&A expenses reaching $4.4 million. Alto completed an upsized IPO in February 2024, netting $133 million in proceeds.
Alto Neuroscience, Inc. ('Alto') (ANRO) announced upcoming data presentations at the Society of Biological Psychiatry and American Society of Clinical Psychopharmacology Annual Meetings, showcasing its precision psychiatry pipeline. The company highlighted neurobiological markers linked to cognitive impairment in schizophrenia and the development of novel compounds for depression and schizophrenia. The ALTO-100 study identified memory-based cognitive markers predicting antidepressant response, while ALTO-101 showed significant effects on electrophysiological measures relevant to cognitive processing. ALTO-300 demonstrated EEG-based cognitive markers predicting greater response. The presentations aim to contribute to the scientific community and further develop treatment options for patients.
Summary not available.
Summary not available.
Summary not available.
Summary not available.